Loading stock data…
MRK
$113.19+0.07 (+0.07%)
Market OpenUpdated 10:27 AM EDT
Merck & Co., Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Merck & Co., Inc. in the Healthcare sector is trading at $113.11. The stock is currently 10% below its 52-week high of $125.14, remaining 14.3% above its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why MRK maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$113.19
Potential Upside
56.3%
Whystock Fair Value$176.91
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus27 analysts
Buy
Mean target$129.74+14.6%
Range$100.00 – $150.00
Fundamentals
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bri...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$279.11B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
15.51
Beta
Defensive asset. Lower volatility than the S&P 500.
0.28
Div Yield
Strong income play. Yield provides a meaningful total return floor.
302.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
31.19%
Volume
Today's trading volume
1.21M
Recent News
Factbox-Global drugmakers rush to boost US presence as tariff threat looms
May 4 (Reuters) - Global drugmakers have been ramping up U.S. manufacturing and stockpiling inventory as the Trump administration moves to impose 100% tariffs on branded drugs unless companies cut
What Makes Merck & Co. (MRK) an Investment Bet?
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. Baron Health Care Fund (the Fund) declined 6.97% (Institutional Shares) in the quarter, compared to the 4.88% decline for the Russell 3000 Health Care Index (the Benchmark) and […]
Warren Buffett Owns 2 of the Small Dogs of the Dow: Here’s Why You Need to Own All 5
The “Dogs of the Dow” is a well-known strategy first published in 1991 by Michael O’Higgins. The plan aims to maximize investment returns by purchasing the 10 highest-yielding dividend stocks in the Dow Jones Industrial Average each year. The highest-yielding stocks are also the lowest-priced stocks in the venerable average, as the lower a stock ... Warren Buffett Owns 2 of the Small Dogs of the Dow: Here’s Why You Need to Own All 5
Do Wall Street Analysts Like Merck & Co. Stock?
Merck & Co. has outperformed the broader market over the past year, and analysts remain moderately optimistic about the stock’s prospects.
The Zacks Analyst Blog Highlights Moderna, Merck and Vertex Pharmaceuticals
Moderna jumps despite a Q1 loss as strong international vaccine sales drive revenue surge and boost investor sentiment.